Langasog, Fe L.

HRN: 18-87-84  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/17/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
05/17/2025
05/30/2025
IV
2.25g
Q6H
Sepsis Secondary To Nonhealing Wound
Waiting Final Action 
05/17/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
05/17/2025
05/29/2025
IV
600mg
Q8H
Sepsis Secondary To Nonhealing Wound
Waiting Final Action 
05/25/2025
MUPIROCIN 2%, 15G (TUBE)
05/25/2025
06/01/2025
DERMAL
1
BID
NONHEALING WOUND
Waiting Final Action 
06/05/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
06/05/2025
06/12/2025
IV
600mg
Q8
S/P BKA, Left
Waiting Final Action 
06/07/2025
CEFTAZIDIME 1GM (VIAL)
06/07/2025
06/13/2025
IV
500 Mg
OD
Sepsis Sec To Infected Wound
Waiting Final Action 
06/07/2025
LEVOFLOXACIN 500MG (TAB)
06/07/2025
06/13/2025
ORAL
500 Mg
OD
CAP MR
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: